Eli Lilly disclosed a series of RXFP1 (relaxin receptor 1) agonists described as candidates for pulmonary hypertension, kidney disease, and cardiorenal conditions (cdd0d021f719f7ee). The compounds were presented in a disclosure outlining chemistry and proposed therapeutic applications. Primary message: Lilly’s RXFP1 agonists demonstrate receptor engagement profiles consistent with vasodilatory and antifibrotic biology, positioning the class for chronic cardiopulmonary and renal indications. The disclosure emphasizes potential breadth across acute and chronic organ dysfunction. For clinical development planners, Lilly’s work signals renewed interest in relaxin biology and suggests opportunities for combination strategies and biomarker-driven patient selection in cardiorenal therapeutics.